Statins: targeting cardiovascular disease

Farouk Mamdoo, Frederick J. Raal


The explosion of medical knowledge and the importance and real reductions in adverse cardiovascular events with improving medical therapy has seen a surge in large trials investigating the use of HMG-CoA reductase inhibitors (statins) in the treatment of patients with cardiovascular disease since the 1990s. The established pathological role of low density lipoprotein (LDL) cholesterol and the efficacy of the lipid lowering properties of statins have ushered in an effective means of managing and preventing major adverse cardiovascular events (MACE). The purpose of this article is to review the evidence to date illustrating the benefits of statin therapy and highlight some of the key features of the landmark trials in order to gain more insight in their use in the acute coronary syndromes.

Full Text:




  • There are currently no refbacks.

ISSN: 2071-4602 (online) ISSN: 1996-6741 (print)

Copyright © 2017 SA Heart Journal

Hosted by Stellenbosch University Library and Information Service since 2017.

Creative Commons License -CC BY-NC-ND 4.0

This journal is hosted by the SU LIS on request of the journal owner/editor. The SU LIS takes no responsibility for the content published within this journal, and disclaim all liability arising out of the use of or inability to use the information contained herein. We assume no responsibility, and shall not be liable for any breaches of agreement with other publishers/hosts.